Media & Resources

DNA Vaccine Delivery Technology Shows Promise in Inducing Stronger Immune Responses SAN DIEGO, August 14, 2008—Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using a proprietary electroporation-based DNA delivery platform, announced today it has expanded its research license with the International AIDS Vaccine Initiative (IAVI), a leading organization dedicated to…

MEXICO CITY, XVII International AIDS Conference, August 7, 2008 – Discussions about how to manage AIDS in the long term and how to improve prevention efforts globally took center stage at this year’s International AIDS Conference (IAC) held in Mexico City. Unlike previous IAC conferences, this year’s event did not have a plenary session focused…

Resetting Expectations in the Search for an AIDS Vaccine In its AIDS Vaccine Blueprint 2008, IAVI proposes a series of interim milestones to help overcome the biggest challenges facing the AIDS vaccine field today MEXICO CITY, August 5, 2008 – With the release of its AIDS Vaccine Blueprint 2008 at the International AIDS Conference today…

Calls for Sustained Funding to Maintain HIV Prevention Research Efforts Mexico City, August 5, 2008 – A new report released today shows that funding for biomedical HIV prevention research and development (R&D), including AIDS vaccines and microbicides, increased dramatically between 2000 and 2006 with only a modest increase in 2007. The report warns that the…

New Prevention Tools Still Needed Urgently In advance of the XVII International AIDS Conference in Mexico City, the Joint United Nations Programme on HIV/AIDS (UNAIDS) released their 2008 Report on the global AIDS epidemic, which indicated, among other things, that new HIV infections and AIDS-related deaths have declined in recent years. According to the new…

As a member of Global Health Technologies Coalition, IAVI applauds the historic bipartisan effort, as well as the bold leadership, of both the Congress and Administration in ensuring that the critical Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis and Malaria Reauthorization Act of 2008 was passed. This important legislation…

NEW YORK, July 17, 2008 —Today, the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) announced that it will not go ahead with the proposed Phase IIb AIDS vaccine trial known as PAVE 100.  The announcement followed the failure last September of an AIDS vaccine candidate with some similarities to…

NEW YORK, July 3, 2008—Dr. Thomas Hassell, former global vice president of process development at sanofi pasteur, the largest vaccine company worldwide, has joined IAVI as vice president for vaccine development. In his new role, Dr. Hassell will lead IAVI’s product development efforts that are aimed at rapidly advancing promising vaccine candidates that emerge from…